Core Viewpoint - 嘉和生物-B reported a significant increase in total revenue for the six months ending June 30, 2025, amounting to approximately RMB 32.2 million, primarily due to a licensing and equity agreement with TRC 2004, Inc. This is a notable increase from approximately RMB 14.5 million for the same period ending June 30, 2024 [1]. Financial Performance - Total revenue for the reporting period was approximately RMB 32.2 million, compared to approximately RMB 14.5 million for the previous year [1]. - Research and development expenses for the reporting period were approximately RMB 74.6 million, down from approximately RMB 109.7 million for the six months ending June 30, 2024 [1]. - The decrease in R&D expenses is attributed to a reduction in employee benefits for R&D personnel and lower costs associated with new drug development and clinical trials [1].
嘉和生物-B(06998.HK)：上半年总收益为3220万元